EMERGENT BIOSOLUTIONS INC. Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation
EMERGENT BIOSOLUTIONS INC. (EBS) reported Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation of $2.20 million for the 12-month period ending 2011-12-31, per its 10-K filed 2012-03-09.
Discontinued › Notes › Compensation Related Costs
us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation · last filed 2012-03-09
- EMERGENT BIOSOLUTIONS INC. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2011 was $2.20M, a 29.41% increase from fiscal 2010.
- EMERGENT BIOSOLUTIONS INC. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2010 was $1.70M, a 8.21% decline from fiscal 2009.
- EMERGENT BIOSOLUTIONS INC. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2009 was $1.85M.
| Period end | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 12 month |
|---|---|
| 2011-12-31 | $2.20M 10-K · filed 2012-03-09 |
| 2010-12-31 | $1.70M 10-K · filed 2012-03-09 |
| 2009-12-31 | $1.85M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |